MediaAlpha vs Nutex Health
MAX and NUTX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MAX and NUTX compare
Nutex Health is the larger company, worth 1.5 times as much as MediaAlpha ($1.3B against $886M).
On earnings, Nutex Health is cheaper: it trades at 8.1× trailing earnings, against 8.3× for MediaAlpha.
MediaAlpha grew revenue faster over the last twelve months (15.2% versus −18.8% for Nutex Health).
Nutex Health keeps more of each dollar of sales as profit, with a net margin of 20.7% compared with 8.4% at MediaAlpha.
Nutex Health scores higher on the StockData Score (15 against 14 for MediaAlpha), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MAX | NUTX |
|---|---|---|
| Size and price | ||
| Market cap | $886M | $1.3B |
| Share price | $14.97 | $189.19 |
| Change, 1 year | 15.6% | 59.2% |
| Change, 5 years | −12.1% | −69.6% |
| Beta (5Y) | 0.87 | 1.86 |
| Employees | 147 | 944 |
| StockData Score | ||
| Total score | 14 | 15 (better) |
| Valuation score | 4 | 4 |
| Growth score | 2 | 2 |
| Performance score | 4 | 4 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.3× | 8.1× (better) |
| P/S | 0.7× (better) | 1.6× |
| P/B | 17.3× | 3.0× (better) |
| EV/EBITDA | 10.8× | 3.6× (better) |
| P/FCF | 16.3× | 5.2× (better) |
| FCF yield | 6.1% | 19.1% (better) |
| Fair value | $36.93 | $570.15 |
| Margin of safety | 59.5% | 66.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 15.2% (better) | −18.8% |
| Revenue growth, 5Y average | 13.7% | 26.1% (better) |
| Net income growth (TTM) | – | 36.5% |
| EPS growth (TTM) | – | 21.2% |
| EPS growth, 5Y average | – | −17.2% |
| Profitability | ||
| Gross margin | 14.8% | 47.8% (better) |
| Operating margin | 7.2% | 39.0% (better) |
| Net margin | 8.4% | 20.7% (better) |
| FCF margin | 4.2% | 31.1% (better) |
| Return on equity | 1002% (better) | 43.8% |
| Return on invested capital | 71.6% | 117% (better) |
| Financial health | ||
| Debt / equity | 3.41 | 0.10 (better) |
| Net debt / EBITDA | 1.67 (better) | −0.62 |
| Interest coverage | 8.8× | 16.2× (better) |
| Current ratio | 1.32 | 4.76 (better) |
| Altman Z-score | 4.45 (better) | 3.75 |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | 7.3% (better) | 4.3% |
| Shareholder yield | 7.3% (better) | 4.3% |
| Ownership | ||
| Held by institutions | 82.2% | 42.9% |
| Held by insiders | 39.2% | – |
| Insider net buying, 12 months | −$122M | $2.2K (better) |
| Short interest, % of float | 9.3% | – |
Go deeper
- MAX stock overview
- MAX income statement
- MAX valuation and score
- NUTX stock overview
- NUTX income statement
- NUTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.